Since the outbreak of the novel coronavirus Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2 or COVID-2019) there has been little empiric evidence as to the efficacy of therapies to help guide the management of this disease. In this webinar, we have experts discussing three different therapies that could be effective in the treatment of COVID: convalescent plasma, serum obtained patients who have recovered from COVID; clazakizumab, a monoclonal antibody that binds to human IL-6; and remdisivir, a nucleotide analog with broad-spectrum antiviral activity. This webinar will be moderated by May Lee, MD from University of Southern California and Isabel Pedraza, MD from Cedars Sinai Medical Center.
Michael Joyner, M.D.
Vice Chair for Research, Department of Anesthesiology and Perioperative Medicine
Consultant, Department of Anesthesiology and Perioperative Medicine
Consultant, Department of Physiology & Biomedical Engineering
Professor of Anesthesiology, Mayo Clinic, Rochester, Minnesota
Stanley Jordan, M.D.
Director, HLA and Transplant Immunology Laboratory, Comprehensive Transplant Center
Director, Division of Nephrology
Medical Director, Kidney Transplant Program, Comprehensive Transplant Center
Medical Director, Human Leukocyte Antigen and Transplant Immunology Laboratory
Medical Director, Kidney Transplant Program
Professor of Medicine
Cedars Sinai Medical Center, Los Angeles, CA.
Jonathan Grein, M.D.
Director, Hospital Epidemiology
Associate Clinical Professor, David Geffen School of Medicine at UCLA
Cedars Sinai Medical Center, Los Angeles